Breaking News
March 25, 2019 - Females on ketogenic diet fail to show metabolic benefits in animal model
March 25, 2019 - Modulating stiffness of blood-forming stem cells could facilitate mobilization procedures
March 25, 2019 - Gene editing regulations to be tightened
March 25, 2019 - CPAP treatment can result in weight loss in people with sleep apnea and obseity
March 25, 2019 - Breast Density Categorization Varies With Screening Modality
March 25, 2019 - Researchers explore link between metal exposure and Parkinson’s symptoms
March 25, 2019 - Later meal timing may contribute to weight gain
March 25, 2019 - Around one in hundred people has autism spectrum condition in China
March 25, 2019 - Research paves way for new standard of care to improve heart’s pump function
March 25, 2019 - Exposure to HIV virus, antiretroviral therapy before birth linked to obesity and asthma-like symptoms
March 25, 2019 - Transgender men preserve their fertility potential after one year of testosterone therapy
March 25, 2019 - Tighter Blood Pressure Control May Prevent Brain Lesions
March 25, 2019 - A reward now or later? Exploring impulsivity in Parkinson’s disease patients
March 25, 2019 - Financial incentives fail to increase completion rates of colorectal cancer screening tests mailed to patients
March 25, 2019 - New research program launched to highlight sexual harassment in academia
March 25, 2019 - Hemoglobin A1c blood test does not detect diabetes in most patients, shows study
March 25, 2019 - Wyss Technology licensed by Sherlock Biosciences to create affordable molecular diagnostics
March 25, 2019 - DWK Life Sciences launches KIMBLE GLS 80 Media Bottle and Multiport Cap System
March 25, 2019 - New study aims to reduce online sexual exploitation of children
March 25, 2019 - Want healthier eating habits? Start with a workout
March 25, 2019 - New approach to prescribing antibiotics could curb resistance
March 24, 2019 - Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
March 24, 2019 - Prenatal DHA prevents blood-pressure increase from obesity during childhood
March 24, 2019 - Combined immunosuppression may be effective, safe in treating older patients with Crohn’s disease
March 24, 2019 - GSK sells health drinks arm, buys US cancer treatment firm
March 24, 2019 - Bacteria and innate immune factors in birth canal, cervix may be key to predicting preterm births
March 24, 2019 - IgG antibodies play unexpected role in atherosclerosis
March 24, 2019 - Sounds and vibrations are quite similar for the brain, finds new study
March 24, 2019 - Practices for Reducing COPD Hospital Readmissions Explored
March 24, 2019 - Could an eye doctor diagnose Alzheimer’s before you have symptoms?
March 24, 2019 - Enzyme inhibitor stops inflammation and neurodevelopmental disorders in mouse models
March 24, 2019 - Walk, Dance, Clean: Even a Little Activity Helps You Live Longer
March 24, 2019 - Americans used less eye care in 2014 versus 2008
March 24, 2019 - Study finds link between depression in 20s linked to memory loss in 50s
March 24, 2019 - New tool helps physiotherapy students to master complex fine motor skills
March 24, 2019 - The AMR Centre secures £2.3m funding boost
March 24, 2019 - Study examines effects of taking ondansetron during first trimester of pregnancy
March 24, 2019 - Researchers identify a more effective treatment for cancer
March 24, 2019 - Open-source solution for multiparametric optical mapping of the heart’s electrical activity
March 24, 2019 - New nanotechnology approach shows promise in treating triple negative breast cancer
March 24, 2019 - Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
March 24, 2019 - Maternal deaths following C-section 50 times higher in Africa compared to high-income countries
March 24, 2019 - Apple watch could detect irregular heart beat says study
March 24, 2019 - Queen Mary University of London’s BCI boosts radionuclide imaging capabilities with MILabs VECTor technology
March 24, 2019 - Girls should be encouraged to gain more ball skills, shows study
March 24, 2019 - Acute doses of synthetic cannabinoid can impair critical thinking and memory
March 24, 2019 - Presence of bacteria in urine does not always point to infection, shows study
March 24, 2019 - Scientists identify a new role for nerve-supporting cells
March 24, 2019 - Hidden differences between pathology of CTE and Alzheimer’s disease discovered
March 24, 2019 - Knowing causative genes of osteoporosis may open door to more effective treatments
March 24, 2019 - Toilet-seat based cardiovascular monitoring system getting ready to begin commercialization
March 24, 2019 - New model for intensive care identifies factors that send ill patients to ICU
March 24, 2019 - Recommendations Issued for HSCT in Multiple Myeloma
March 24, 2019 - Deep brain stimulation provides sustained relief for severe depression
March 24, 2019 - “Statistical significance” may soon be a thing of past?
March 24, 2019 - Researchers track effects of epigenetic marks carried by sperm chromosomes
March 24, 2019 - AHA News: Family Adopts Three Children With Three Different Heart Conditions
March 24, 2019 - Research into opioid painkillers could provide clues for safer drug development
March 23, 2019 - Lung cancer survivor recounts her lifetime struggles
March 23, 2019 - Radial and femoral approach for PCI achieve similar results in terms of survival
March 23, 2019 - Study sheds light on the optimal timing of coronary angiography in NSTEMI patients
March 23, 2019 - Excess hormones could cause a condition that can lead to blindness in women, study finds
March 23, 2019 - Dramatic shifts in first-time opioid prescriptions bring hope, concern
March 23, 2019 - Antidepressant drugs may not work when neurons are out of shape
March 23, 2019 - TTUHSC El Paso to establish endowed chair in neurology through a major grant
March 23, 2019 - New device approved by FDA for treating patients with moderate-to-severe heart failure
March 23, 2019 - People with peripheral artery disease have lower Omega-3 Index, shows research
March 23, 2019 - Trigger warnings have minimal impact on how people respond to content, shows research
March 23, 2019 - Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
March 23, 2019 - Selfish genetic elements amplify inflammation and age-related diseases
March 23, 2019 - Study provides new understanding of how the brain recovers from damage caused by stroke
March 23, 2019 - CRISPR/Cas libraries could revolutionize drug discovery
March 23, 2019 - Allergic reaction during pregnancy may alter sexual-development in offspring’s brain
March 23, 2019 - Seeing through a robot’s eyes helps those with profound motor impairments
March 23, 2019 - Recent research shows that ease of breastfeeding after C-section differs culturally
March 23, 2019 - Newly discovered parameters offer more control over efficient release of drugs
March 23, 2019 - ‘De-tabooing’ of abortion- Women would like more support from health care community
March 23, 2019 - Anti-TB drugs can increase susceptibility to Mtb reinfection
March 23, 2019 - New survey indicates need of attention to neglected tropical diseases
March 23, 2019 - Innovative in vitro method to develop easy-to-swallow medicine for children and older people
Newly developed drug compound may help treat Charcot-Marie-Tooth disease

Newly developed drug compound may help treat Charcot-Marie-Tooth disease

image_pdfDownload PDFimage_print

Scientists have developed a new drug compound that shows promise as a future treatment for Charcot-Marie-Tooth disease, an inherited, often painful neurodegenerative condition that affects nerves in the hands, arms, feet and legs. The researchers used the compound to treat the nerves of mice harboring the genetic defects that cause the disease.

The new study, from Washington University School of Medicine in St. Louis, challenges some conventional wisdom regarding how patients with this disease lose the ability to move their limbs.

The study appears April 20 in the journal Science.

Charcot-Marie-Tooth is the most common inherited degenerative disease of peripheral nerves. The disease affects about one in 2,500 individuals worldwide, and there are no treatments for it. The researchers studied a form of the condition called Charcot-Marie-Tooth disease type 2A, which is caused by specific genetic mutations.

These patients have inherited mutations that affect mitochondria, the energy factories of cells. Healthy mitochondria fuse together and exchange mitochondrial DNA. This healthy mitochondrial “sex” is impaired in this disease because of mutations in a protein called mitofusin2, which governs mitochondrial fusion.

Because they can’t fuse, the mitochondria of people with this disease appear small, granular and clumped when viewed under a microscope. Until now, the small size was thought to be the main problem in the disorder. Small energy factories can’t produce enough fuel to keep nerves alive, so the cells slowly die off, the thinking went. But senior author Gerald W. Dorn II, MD, the Philip and Sima K. Needleman Professor of Medicine, suspected something else was going on.

Dorn knew the genetic mutations in this disease aren’t confined to nerves; rather, they are present in all of the mitochondria in every cell of the body. Nerve cells and, for example, heart muscle cells burn energy at high rates and need healthy, robust mitochondria for fuel. A cardiologist by training, Dorn wondered why patients with the disease don’t have heart problems.

“This disease starts with nerve loss in the feet, moves up the legs, then to the arms, but it doesn’t have major effects elsewhere,” said Dorn, also director of the School of Medicine’s Center for Pharmacogenomics. “People with Charcot-Marie-Tooth eventually may need wheelchairs, but they have normal lifespans.

“We found that the problem isn’t mitochondria that are too small, but mitochondria that can’t travel distances. In heart cells, mitochondria are packed like sardines and don’t need to move much, so there’s no problem with energy supply,” he said. “But for mitochondria to make it down a person’s leg -; following the sciatic nerve from the lumbar spine to the foot -; that’s akin to a 500-mile trip. If a person can’t constantly renew mitochondria, over the years the nerves start to atrophy. Once the nerves die, the muscles atrophy as well.”

With distance identified as a key factor, the ideal animal model to study this disease, Dorn quipped, is the giraffe. But since that’s not an option and mice don’t develop symptomatic Charcot-Marie-Tooth (because mice are small and their mitochondria don’t have far to go), Dorn and his colleagues extracted sciatic nerves -; the longest nerve in the body -; from mice and set up a way to compare the speeds of mitochondria moving up and down the nerves.

Co-first author Antonietta Franco, PhD, a postdoctoral researcher, found that mitochondria in the mouse nerves with Charcot-Marie-Tooth type 2A mutations were almost static, moving very little in the time frame observed, even when sped up with time-lapse photography. In contrast, mitochondria moving along the nerve axons of normal mice, viewed under the same time-lapse conditions, resembled an aerial shot of a highway.

The researchers then added a drug compound to the nerves with the static mitochondria. This drug, which they designed, works something like a chemical key that unlocks mitofusin2 and boosts mitochondrial fusion. The work developing the drug compound was led by co-first author Agostinho G. Rocha, PhD, a staff scientist.

“After about 15 minutes of exposure to the compound, the mitochondrial traffic began to pick up,” Dorn said. “And after an hour, it looked like the normal nerve. We also found that the drug doesn’t have an effect when added to normal nerves. Mitochondria appear to have a speed limit.”

While the researchers know this drug boosts the ability of diseased mitochondria to fuse to one another, Dorn said it’s possible this is not what lets them move. It may be that the unlocked form of mitofusin2 also lets mitochondria couple to what Dorn calls the railroad tracks of cells. But more research is needed to answer that question.

Dorn said these findings may be relevant for other neurodegenerative disorders in which mitochondria are impaired, including other types of Charcot-Marie-Tooth disease.

Tagged with:

About author

Related Articles